Novo Nordisk’s GLP-1 Franchise Buoyed By SUSTAIN FORTE data
Showed Superior Diabetes Risk-Benefit From Higher Ozempic Dose
Executive Summary
Reductions in blood glucose seen in the SUSTAIN FORTE study using a higher dose of Ozempic may help type 2 diabetes patients further improve their diabetes control, with comparable tolerability to currently approved Ozempic 1.0 mg.
You may also be interested in...
Nine Endocrine And Metabolic Disease Drug Launches To Look Out For In 2022
In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are nine new products for endocrine and metabolic disorders that could make their debuts next year.
Lilly's Tirzepatide Shows Up Novo's Ozempic In Head-To-Head Diabetes Trial
The dual GLP-1/GIP agonist outpaced Novo's blockbuster GLP-1 analogue at all three doses, including the important low dose, on A1C reduction and weight reduction in patients with type 2 diabetes.
Zealand Pharma Preps Pipeline For Catalyst-Filled 2020
Zealand Pharma’s recently installed CEO says it is building US operations to prepare for four potential approvals there in 2020, with commercial launches starting in 2021, its first ever.